Clinical application of circRNA in non-small cell lung cancer

Abstract

Lung cancer is one of the most common cancers in the world, which seriously affects people′s physical and mental health. About 85% of them are non-small cell lung cancers. In recent years, with the rapid development of low-dose computed tomography, Da Vinci robotic surgery and targeted therapy, the therapeutic effect of lung cancer has been greatly improved. However, due to the lack of early diagnosis of biomarkers, therapeutic targets and signs of prognosis, most patients have metastases when they are at the time of treatment. Lung cancer remains the leading cause of cancer-related death. CircRNA is a special endogenous non coding RNA, which is formed by the reverse splicing of the 3′ splice donor site and the 5′ splice acceptor site to form a covalent closed loop. It is highly conservative and stable. The expression level of circRNA in non-small cell lung cancer is obviously abnormal, which is closely related to the occurrence, development and metastasis of non-small cell lung cancer. It is expected to become an ideal biomarker, which is used for early diagnosis of non-small cell lung cancer, and provides new therapeutic targets and prognostic markers. Key words: Non-small-cell lung cancer; Diagnosis; Molecular targeted therapy; Prognosis; Non-coding RNA